| Literature DB >> 31293908 |
Yuan Li1, Shousheng Liu2,3, Yuqiang Gao1, Huan Ma1, Shuhui Zhan1, Yan Yang1, Yongning Xin1,4,3, Shiying Xuan1,3.
Abstract
Background and Aims: Colorectal cancer is associated with non-alcoholic fatty liver disease (NAFLD) and other metabolic syndromes, such as obesity, abnormal blood glucose, and dyslipidemia. The relationship of NAFLD and colorectal adenoma, which is the precursor of colorectal cancer, is worthy of discussion. The aim of this study was to investigate the association between colorectal adenoma and NAFLD, colorectal adenoma and metabolic syndrome in a Chinese Han population.Entities:
Keywords: Colorectal adenoma; Controlled attenuation parameter (CAP); Metabolic syndrome; Non-alcoholic fatty liver disease (NAFLD)
Year: 2019 PMID: 31293908 PMCID: PMC6609839 DOI: 10.14218/JCTH.2019.00010
Source DB: PubMed Journal: J Clin Transl Hepatol ISSN: 2225-0719
Fig. 1.Flowchart of the study participant recruitment process.
Clinical and biochemical characteristics of patients with or without CRA
| Characteristic | CRA patients, | Controls, | |
| Age in years | 54.5 ± 0.38 | 54.44 ± 0.68 | 0.930 |
| NAFLD | 142 (53.2%) | 360 (43.8%) | 0.008 |
| CAP | 235.56 ± 30.82 | 219.12 ± 29.55 | 0.002 |
| BMI in Kg/m2 | 24.54 ± 1.27 | 24.22 ± 0.62 | <0.001 |
| TG in mmol/L | 1.99 ± 1.32 | 1.45 ± 0.88 | <0.001 |
| TC in mmol/L | 5.55 ± 0.98 | 5.46 ± 1.08 | 0.206 |
| HDL-C in mmol/L | 1.32 ± 0.37 | 1.39 ± 0.32 | 0.003 |
| LDL-C in mmol/L | 3.27 ± 0.77 | 3.25 ± 0.82 | 0.681 |
| AST in mmol/L | 34.5 ± 8.20 | 29.7 ± 7.80 | 0.003 |
| ALT in mmol/L | 31.9 ± 11.10 | 30.3 ± 9.9 | 0.321 |
| FPG in mmol/L | 5.22 ± 0.99 | 4.84 ± 0.77 | <0.001 |
| UA in mmol/L | 369.61 ± 84.26 | 337.77 ± 86.01 | <0.001 |
Abbreviations: NAFLD, non-alcoholic fatty liver disease; CAP, controlled attenuation parameter; BMI, body mass index; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FPG, fasting plasma glucose; UA, uric acid.
Data are presented as mean ± SD or n (%).
Multiple factor logistic regression analysis of the risk of CRA
| Characteristic | OR | 95% CI | |
| Age | 1.004 | 0.988–1.022 | 0.611 |
| Sex | 42.170 | 21.498–82.720 | <0.001 |
| NAFLD | 1.425 | 1.112–2.042 | 0.018 |
| CAP | 1.139 | 1.047–1.240 | 0.003 |
| BMI | 1.468 | 1.199–1.797 | <0.001 |
| TG | 1.248 | 1.003–1.554 | 0.047 |
| TC | 1.105 | 0.660–1.852 | 0.704 |
| HDL-C | 0.962 | 0.307–1.329 | 0.230 |
| LDL-C | 0.906 | 0.504–1.835 | 0.906 |
| AST | 1.364 | 1.275–1.621 | 0.002 |
| ALT | 1.123 | 0.786–1.435 | 0.561 |
| FPG | 1.514 | 1.218–1.882 | <0.001 |
| UA | 1.002 | 1.000–1.004 | 0.124 |
Abbreviations: OR, odds ratio; CI, confidence interval; NAFLD, non-alcoholic fatty liver disease; CAP, controlled attenuation parameter; BMI, body mass index; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FPG, fasting plasma glucose; UA, uric acid.
Clinical and biochemical characteristics of both sexes of patients with or without CRA
| Characteristic | Male, | Female, | ||||
| CRA patients, | Controls, | CRA patients, | Controls, | |||
| Age in years | 53.49 ± 10.18 | 53.93 ± 11.22 | 0.648 | 56.31 ± 9.75 | 55.02 ± 10.58 | 0.282 |
| NAFLD | 93 (53.1%) | 166 (42.5%) | 0.018 | 49 (53.3%) | 195 (45.2%) | 0.160 |
| CAP in dB/m | 241.62 ± 30.57 | 225.58 ± 29.12 | 0.001 | 220.67 ± 25.56 | 215.45 ± 27.68 | 0.761 |
| BMI in Kg/m2 | 24.72 ± 1.14 | 24.33 ± 0.63 | <0.001 | 24.20 ± 1.44 | 24.12 ± 0.59 | 0.371 |
| TG in mmol/L | 2.01 ± 1.25 | 1.54 ± 0.96 | <0.001 | 1.94 ± 1.45 | 1.38 ± 0.79 | <0.001 |
| TC in mmol/L | 5.44 ± 0.96 | 5.43 ± 1.06 | 0.904 | 5.72 ± 1.09 | 5.49 ± 1.10 | 0.065 |
| HDL-C in mmol/L | 1.27 ± 0.30 | 1.38 ± 0.33 | <0.001 | 1.43 ± 0.47 | 1.41 ± 0.32 | 0.694 |
| LDL-C in mmol/L | 3.22 ± 0.73 | 3.23 ± 0.81 | 0.912 | 3.37 ± 0.84 | 3.27 ± 0.83 | 0.284 |
| AST in mmol/L | 36.70 ± 11.40 | 27.60 ± 10.30 | <0.001 | 33.20 ± 12.30 | 31.90 ± 12.70 | 0.059 |
| ALT in mmol/L | 33.30 ± 7.80 | 32.40 ± 9.20 | 0.871 | 29.10 ± 9.30 | 28.30 ± 10.90 | 0.584 |
| FPG in mmol/L | 5.18 ± 0.99 | 4.85 ± 0.80 | <0.001 | 5.50 ± 1.01 | 4.83 ± 0.74 | <0.001 |
| UA in mmol/L | 382.97 ± 84.53 | 353.38 ± 84.78 | <0.001 | 343.78 ± 77.55 | 323.61 ± 84.76 | 0.027 |
Abbreviations: NAFLD, non-alcoholic fatty liver disease; CAP, controlled attenuation parameter; BMI, body mass index; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FPG, fasting plasma glucose; UA, uric acid.
Data are presented as mean ± SD or n (%).
Multiple factor logistic regression analysis of the risk of CRA in both sexes of subjects
| Characteristic | Male | Female | ||||
| OR | 95% CI | OR | 95% CI | |||
| Age | 1.006 | 0.988–1.024 | 0.535 | 1.009 | 0.985–1.034 | 0.449 |
| NAFLD | 1.473 | 1.003–2.162 | 0.048 | 1.316 | 0.817–2.12 | 0.259 |
| CAP | 1.765 | 1.598–2.068 | 0.002 | 1.165 | 0.714–1.461 | 0.124 |
| BMI | 1.833 | 1.409–2.385 | <0.001 | 1.073 | 0.797–1.443 | 0.643 |
| TG | 1.200 | 0.952–1.512 | 0.123 | 1.696 | 1.254–2.293 | 0.001 |
| TC | 1.127 | 0.632–2.009 | 0.686 | 0.838 | 0.501–1.402 | 0.501 |
| HDL-C | 0.532 | 0.234–1.213 | 0.133 | 2.629 | 1.106–6.249 | 0.029 |
| LDL-C | 0.917 | 0.445–1.887 | 0.814 | 1.311 | 0.685–2.508 | 0.414 |
| AST | 1.761 | 1.452–2.004 | 0.001 | 1.327 | 0.784–1.754 | 0.086 |
| ALT | 1.212 | 0.674–1.297 | 0.154 | 1.132 | 0.934–1.432 | 0.463 |
| FPG | 1.511 | 1.200–1.901 | <0.001 | 1.565 | 1.174–2.087 | 0.002 |
| UA | 1.002 | 1.000–1.005 | 0.065 | 1.001 | 0.998–1.004 | 0.534 |
Abbreviations: OR, odds ratio; CI, confidence interval; NAFLD, non-alcoholic fatty liver disease; CAP, controlled attenuation parameter; BMI, body mass index; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FPG, fasting plasma glucose; UA, uric acid.